No Mortality Difference Found With Paclitaxel-Coated Devices in Interim Analysis of SWEDEPAD Trial
December 9, 2020—In The New England Journal of Medicine (NEJM), Joakim Nordanstig, MD, et al published findings from an unplanned interim analysis of all-cause mortality in the SWEDEPAD clinical trial, in which patients with peripheral artery disease received treatment with paclitaxel-coated or uncoated endovascular devices.
